Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-28 @ 10:37 AM
Study NCT ID:
NCT05505292
Status:
COMPLETED
Last Update Posted:
2025-01-14
First Post:
2022-08-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Sponsor:
State University of New York College of Optometry
Organization:
Study Overview
Official Title:
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Status:
COMPLETED
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: